MedTrace Logo

Symptom Based Treatment Affects Brain Plasticity - the Role of Verbal Auditory Hallucinations

NCT02722915 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2020-01-09

No results posted yet for this study

Summary

The aim of the study is the examination of brain plasticity on verbal auditory hallucinations (AVH) after neuromodulation with fMRI (functional magnetic resonance imaging) neurofeedback. During the training of fMRI neurofeedback subjects are trained to regulate consciously the connectivity of areas which are associated with hallucinations.The aim is to improve perceived hallucinations' intensity in everyday life of the patients as well as investigating the impact of neurofeedback on resting-state networks in the brain. As control groups, control subjects without AVH and participants with AVH, but no psychiatric diagnosis will be included.

Conditions

  • Hallucinations, Verbal Auditory

Interventions

PROCEDURE

fMRI

collection of functional brain data for 1 hour per day

BEHAVIORAL

Neurofeedback

Task of the participants is to increase or decrease the connectivity between selected brain regions in double-blind, randomized order. After the regulation they will get a feedback about the regulation success. (Patients and controls with AVH: days 3 \& 4; controls without AVH: Days 2 \& 3)

OTHER

PANAS

to assess the mood before and after the fMRI and after 1 week during a telephone interview

OTHER

AVHRS

to assess the intensity and quality of the hallucinations before and after the fMRI and after 1 week during a telephone interview

OTHER

SF36

questionnaire about life quality after 1 week during a telephone interview

Sponsors & Collaborators

  • RWTH Aachen University

    lead OTHER

Principal Investigators

  • Klaus Mathiak, Prof MD PhD · University Hospital RWTH Aachen, Department of Psychiatry, Psychotherapy and Psychosomatics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02722915 on ClinicalTrials.gov